Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

The French drugmaker added the BTK inhibitor tolebrutinib to its pipeline by acquiring Principia for $3.7 billion. Facing down skepticism, Sanofi guided the asset to mixed phase 3 data last year ...

Tolebrutinib has been submitted in line with ... This is a demonstration of Sanofi's commitment, unwavering commitment to patients with MS. Thanks very much. I'll just, go simple and try to ...

Sanofi (NASDAQ: SNY) Q4 2024 Earnings Call Jan 30, 2025, 9:00 a.m. ET Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. Contents: Prepared Remarks ...

Sanofi also has a strong immunology and neuro-inflammation pipeline, which includes some potential blockbuster assets in phase III development, including amlitelimab, frexalimab and tolebrutinib.

Sanofi (NASDAQ:SNY) Q4 2024 Earnings Call Transcript ... we're pleased with the positive Phase 3 results of fitusiran, rilzabrutinib, and tolebrutinib. They provide the foundation for potential ...

Sanofi: Q4 sales growth of 10.3% ... 3 study results for new medicines such as rilzabrutinib in rare diseases and tolebrutinib in multiple sclerosis. As we enter 2025, we expect continued ...

Sanofi confirms the expectation of a strong ... results for new medicines such as rilzabrutinib in rare diseases and tolebrutinib in multiple sclerosis. As we enter 2025, we expect continued ...

Phase 3 trial results Tolebrutinib (Sanofi) Brain-penetant Bruton tyrosine kinase inhibitor Treatment of adults with non-relapsing secondary progressive multiple sclerosis. Breakthrough Therapy ...